Market Price

73.05 

0.22 0.3%

as of May 17 '21

52 Week Range:

30.83 92.60


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in Phase I/II clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase I/II clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase I/II clinical trial for treating liver diseases; ARO-ENaC, which is in Phase I/II clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase Ib for the treatment of clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular target. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Sep '10 Sep '11 Sep '12 Sep '13 Sep '14 Sep '15 Sep '16 Sep '17 Sep '18 Sep '19 Sep '20
Equity (BVPS) 1.26
1.48
0.69
1.08
3.41
2.21
0.86
1.20
1.15
2.37
4.82
growth rate 17.5% -53.4% 56.5% 215.7% -35.2% -61.1% 39.5% -4.2% 106.1% 103.4%
Earnings BIT -4.31
-8.79
-22.11
-31.70
-48.73
-83.94
-85.55
-37.00
-55.94
61.19
-93.16
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% -100.0%
Avg.PE -18.30
-5.90
-2.40
-1.43
-1.43
-1.43
-1.43
-5.69
-5.69
98.63
481.35
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% 388.0%
ROA -57.58
-22.16
-130.34
-115.65
-53.26
-58.36
-62.76
-29.61
-50.50
29.46
-19.39
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% -100.0%
ROE -83.06
-28.66
-185.28
-166.05
-60.43
-66.45
-79.44
-38.85
-61.45
39.94
-23.94
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% -100.0%
ROIC -76.32
-27.15
-162.74
-147.77
-59.41
-66.03
-78.11
-37.73
-59.81
39.94
-22.59
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% -100.0%
Cur. Ratio 1.90
3.82
1.23
3.31
13.07
6.47
3.53
3.63
6.37
2.73
7.92
growth rate 101.1% -67.8% 169.1% 294.9% -50.5% -45.4% 2.8% 75.5% -57.1% 190.1%
Quick Ratio 1.82
3.78
1.12
3.24
13.01
6.21
3.33
3.51
6.22
2.67
7.77
growth rate 107.7% -70.4% 189.3% 301.5% -52.3% -46.4% 5.4% 77.2% -57.1% 191.0%
Leverage 1.37
1.24
1.65
1.36
1.10
1.20
1.34
1.28
1.17
1.43
1.13
growth rate -9.5% 33.1% -17.6% -19.1% 9.1% 11.7% -4.5% -8.6% 22.2% -21.0%
Balance Sheet Sep '10 Sep '11 Sep '12 Sep '13 Sep '14 Sep '15 Sep '16 Sep '17 Sep '18 Sep '19 Sep '20
Acct.Receivable 0.10
1.61
2.47
0.08
0.08
0.08
0.08
0.07
0.33
0.66
0.85
growth rate 1,508.0% 53.3% -97.0% 0.0% 0.0% 0.0% -9.6% 382.9% 102.0% 27.9%
Acct.Payable 1.64
2.74
2.74
2.58
5.03
12.23
4.08
2.81
7.65
6.83
growth rate 67.1% 0.3% -6.0% 95.1% 143.1% -66.7% -31.2% 172.6% -10.7%
Cur.Assets 8.10
9.86
6.57
28.84
154.80
102.87
90.50
67.90
78.77
265.25
322.37
growth rate 21.7% -33.4% 339.2% 436.7% -33.6% -12.0% -25.0% 16.0% 236.7% 21.5%
Total Assets 12.40
15.89
16.53
37.33
182.82
132.27
128.18
104.02
111.61
349.85
522.50
growth rate 28.1% 4.0% 125.9% 389.7% -27.7% -3.1% -18.8% 7.3% 213.5% 49.4%
Cash 6.80
7.51
3.38
19.11
132.51
81.21
85.37
24.84
30.13
221.80
143.58
growth rate 10.4% -55.0% 466.0% 593.3% -38.7% 5.1% -70.9% 21.3% 636.1% -35.3%
Inventory 0.00 0.00 0.00
growth rate
Cur.Liabilities 4.30
2.58
5.33
8.73
11.85
15.90
25.64
18.70
12.37
97.07
40.68
growth rate -40.0% 106.4% 63.8% 35.8% 34.2% 61.3% -27.1% -33.9% 685.0% -58.1%
Liabilities 3.30
3.32
7.72
11.60
16.83
22.65
33.15
23.16
16.37
105.81
60.72
growth rate 0.7% 132.2% 50.2% 45.2% 34.6% 46.4% -30.2% -29.3% 546.4% -42.6%
LT Debt 0.00
0.61
2.12
1.11
0.76
0.54
2.53
2.33
2.10
growth rate 249.6% -47.6% -31.8% -28.7% 368.5% -8.2% -9.6%
Equity 9.00
12.79
10.01
27.50
166.54
110.18
95.58
81.42
95.80
244.59
461.78
growth rate 42.1% -21.7% 174.6% 505.6% -33.8% -13.3% -14.8% 17.7% 155.3% 88.8%
Common Shares 6.00
7.00
11.00
24.00
47.00
57.00
61.00
74.00
84.00
99.00
101.00
growth rate 16.7% 57.1% 118.2% 95.8% 21.3% 7.0% 21.3% 13.5% 17.9% 2.0%
Cash Flow Statement Sep '10 Sep '11 Sep '12 Sep '13 Sep '14 Sep '15 Sep '16 Sep '17 Sep '18 Sep '19 Sep '20
Capital Expenditures 0.00
0.01
0.48
0.30
1.72
1.97
3.86
7.92
1.42
12.00
11.95
growth rate 4,700.0% -38.1% 478.3% 14.7% 95.9% 105.1% -82.1% 744.4% -0.4%
Cash Dividends 0.00 0.00 0.00
growth rate
Cash From OA -7.70
-5.39
-15.34
-35.42
-65.71
-64.43
-23.94
-47.22
173.03
-95.39
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% -100.0%
FCF per Share -1.20
-0.69
-1.29
-0.59
-0.72
-1.18
-1.14
-0.50
-0.68
1.59
-0.88
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% -100.0%
Sale Purchase of Stock 6.23
10.97
44.51
139.52
0.50
55.98
12.69
growth rate 76.1% 305.9% 213.5% -99.6% 10,996.9% -77.3%
FCF -8.00
-5.00
-16.00
-19.00
-37.00
-68.00
-68.00
-32.00
-49.00
161.00
-107.00
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% -100.0%
Income Statement Sep '10 Sep '11 Sep '12 Sep '13 Sep '14 Sep '15 Sep '16 Sep '17 Sep '18 Sep '19 Sep '20
Sales 0.00
0.30
0.15
0.29
0.18
0.38
0.16
31.41
16.14
168.80
87.99
growth rate -50.3% 97.3% -39.7% 118.3% -58.6% 19,740.6% -48.6% 945.7% -47.9%
Op.Income -5.80
-8.79
-22.11
-31.70
-48.73
-83.94
-85.55
-37.00
-55.94
61.19
-93.16
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% -100.0%
IBT -4.30
-8.79
-22.11
-31.70
-58.72
-91.94
-81.72
-34.38
-54.45
68.15
-84.55
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% -100.0%
Net Income -5.80
-8.79
-22.11
-31.70
-58.63
-91.94
-81.72
-34.38
-54.45
67.97
-84.55
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% -100.0%
EPS -0.90
-0.44
-1.90
-1.30
-1.25
-1.60
-1.34
-0.47
-0.65
0.69
-0.84
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% -100.0%
Gross Profit 0.00
0.30
0.15
0.29
0.18
0.38
0.16
31.41
16.14
168.80
87.99
growth rate -50.3% 97.3% -39.7% 118.3% -58.6% 19,740.6% -48.6% 945.7% -47.9%
R&D 0.50
3.28
5.39
8.71
22.78
46.74
60.80
48.60
52.97
78.40
124.74
growth rate 555.6% 64.5% 61.5% 161.6% 105.2% 30.1% -20.1% 9.0% 48.0% 59.1%

Quarterly Statements

Item Name Mar '20 Jun '20 Sep '20 Dec '20 Mar '21
Earnings BIT -22.24
-15.95
-50.12
-24.05
-28.23
growth rate 0.0% 0.0% 0.0% 0.0%
Balance Sheet Mar '20 Jun '20 Sep '20 Dec '20 Mar '21
Acct.Receivable 1.27
21.69
0.85
9.00
0.96
growth rate 1,613.8% -96.1% 964.4% -89.4%
Acct.Payable 13.42
4.07
6.83
4.83
5.30
growth rate -69.6% 67.6% -29.3% 9.8%
Cur.Assets 314.47
315.23
322.37
323.72
586.76
growth rate 0.2% 2.3% 0.4% 81.3%
Total Assets 561.08
555.73
522.50
499.25
756.80
growth rate -1.0% -6.0% -4.5% 51.6%
Cash 256.65
219.32
143.58
139.92
372.40
growth rate -14.5% -34.5% -2.6% 166.2%
Cur.Liabilities 53.33
42.78
40.68
25.09
167.19
growth rate -19.8% -4.9% -38.3% 566.3%
Liabilities 67.51
63.14
60.72
44.78
growth rate -6.5% -3.8% -26.3%
LT Debt
growth rate
Equity 494.12
493.14
461.78
454.47
growth rate -0.2% -6.4% -1.6%
Common Shares 0.19
0.19
0.19
0.20
0.20
growth rate 0.3% 0.1% 0.2% 0.5%
Cash Flow Statement Mar '20 Jun '20 Sep '20 Dec '20 Mar '21
Capital Expenditures 3.61
2.14
1.88
4.27
growth rate -40.8% -11.9% 126.7%
Cash Dividends
growth rate
Cash From OA -27.58
-33.43
-10.85
-38.92
growth rate 0.0% 0.0% 0.0%
Sale Purchase of Stock
growth rate
FCF -31.19
-35.57
-12.73
-43.19
growth rate 0.0% 0.0% 0.0%
Income Statement Mar '20 Jun '20 Sep '20 Dec '20 Mar '21
Sales 23.53
27.38
7.63
21.30
32.81
growth rate 16.4% -72.1% 179.1% 54.0%
Op.Income -22.24
-15.95
-50.12
-24.05
-28.23
growth rate 0.0% 0.0% 0.0% 0.0%
IBT -19.84
-13.61
-48.43
-20.73
-26.82
growth rate 0.0% 0.0% 0.0% 0.0%
Net Income -19.84
-13.61
-48.43
-20.73
-26.82
growth rate 0.0% 0.0% 0.0% 0.0%
EPS
growth rate
Gross Profit 23.53
27.38
7.63
21.30
32.81
growth rate 16.4% -72.1% 179.1% 54.0%
R&D 29.16
31.36
42.00
35.08
growth rate 7.6% 33.9% -16.5%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

F (16.19)

YOY Growth Grade:

F (0.00)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 481.35 811.67 -132.42
EPS / Growth 0.0% 0.09 7.3%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 50.0%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 0.0% 19.1% 22.3%
Future PE 0.00 19.12 22.28
Future EPS 0.09 0.52 0.67
Value Price
MOS %
0.00
-100.0%
2.44
-96.7%
3.70
-94.9%
MOS Price 0.00 1.22 1.85
IRT 99.00 27.88 24.87

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.